DE10205520A1 - Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease - Google Patents

Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease

Info

Publication number
DE10205520A1
DE10205520A1 DE10205520A DE10205520A DE10205520A1 DE 10205520 A1 DE10205520 A1 DE 10205520A1 DE 10205520 A DE10205520 A DE 10205520A DE 10205520 A DE10205520 A DE 10205520A DE 10205520 A1 DE10205520 A1 DE 10205520A1
Authority
DE
Germany
Prior art keywords
fsap
monoclonal antibody
mab
antibody
proenzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10205520A
Other languages
German (de)
English (en)
Inventor
Juergen Roemisch
Wiegand Lang
Annette Feussner
Gudrun Muth-Naumann
Hans-Arnold Stoehr
Christian Kannemeier
Klaus Preissner
Fumie Nakazawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
Aventis Behring GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Behring GmbH filed Critical Aventis Behring GmbH
Priority to DE10205520A priority Critical patent/DE10205520A1/de
Priority to DE50302926T priority patent/DE50302926D1/de
Priority to AT03000857T priority patent/ATE323107T1/de
Priority to DK03000857T priority patent/DK1334983T3/da
Priority to EP03000857A priority patent/EP1334983B1/de
Priority to ES03000857T priority patent/ES2259114T3/es
Priority to CA2418411A priority patent/CA2418411C/en
Priority to KR1020030007874A priority patent/KR100972943B1/ko
Priority to AU2003200420A priority patent/AU2003200420B2/en
Priority to US10/359,704 priority patent/US7829095B2/en
Priority to JP2003030238A priority patent/JP4398648B2/ja
Publication of DE10205520A1 publication Critical patent/DE10205520A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96447—Factor VII (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE10205520A 2002-02-08 2002-02-08 Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease Withdrawn DE10205520A1 (de)

Priority Applications (11)

Application Number Priority Date Filing Date Title
DE10205520A DE10205520A1 (de) 2002-02-08 2002-02-08 Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease
DE50302926T DE50302926D1 (de) 2002-02-08 2003-01-15 Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII akitivierende Protease
AT03000857T ATE323107T1 (de) 2002-02-08 2003-01-15 Inhibitorischer, monoklonaler antikörper gegen die den blutgerinnungsfaktor vii akitivierende protease
DK03000857T DK1334983T3 (da) 2002-02-08 2003-01-15 Inhiberende monoklonalt antistof med proeasen, som aktiverer blodkoaguleringsfaktor VII
EP03000857A EP1334983B1 (de) 2002-02-08 2003-01-15 Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII akitivierende Protease
ES03000857T ES2259114T3 (es) 2002-02-08 2003-01-15 Anticuerpo monoclonal inhibidor contra la proteasa activadora del factor vii de coagulacion sanguinea.
CA2418411A CA2418411C (en) 2002-02-08 2003-02-03 Inhibitory, monoclonal antibody against blood clotting factor vii-activating protease
KR1020030007874A KR100972943B1 (ko) 2002-02-08 2003-02-07 혈액 응고 인자 ⅶ-활성화 프로테아제에 대한 억제모노클로날 항체
AU2003200420A AU2003200420B2 (en) 2002-02-08 2003-02-07 Inhibitory, Monoclonal antibody against blood clotting factor VII-activating protease
US10/359,704 US7829095B2 (en) 2002-02-08 2003-02-07 Inhibitory monoclonal antibody against blood clotting factor VII-activating protease
JP2003030238A JP4398648B2 (ja) 2002-02-08 2003-02-07 血液凝固第ｖｉｉ因子活性化プロテアーゼに対する抑制性モノクローナル抗体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10205520A DE10205520A1 (de) 2002-02-08 2002-02-08 Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease

Publications (1)

Publication Number Publication Date
DE10205520A1 true DE10205520A1 (de) 2003-08-14

Family

ID=27588518

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10205520A Withdrawn DE10205520A1 (de) 2002-02-08 2002-02-08 Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease
DE50302926T Expired - Lifetime DE50302926D1 (de) 2002-02-08 2003-01-15 Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII akitivierende Protease

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE50302926T Expired - Lifetime DE50302926D1 (de) 2002-02-08 2003-01-15 Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII akitivierende Protease

Country Status (10)

Country Link
US (1) US7829095B2 (enExample)
EP (1) EP1334983B1 (enExample)
JP (1) JP4398648B2 (enExample)
KR (1) KR100972943B1 (enExample)
AT (1) ATE323107T1 (enExample)
AU (1) AU2003200420B2 (enExample)
CA (1) CA2418411C (enExample)
DE (2) DE10205520A1 (enExample)
DK (1) DK1334983T3 (enExample)
ES (1) ES2259114T3 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19903693A1 (de) * 1998-04-24 1999-10-28 Centeon Pharma Gmbh Protease zur Aktivierung des Gerinnungsfaktors VII
DE10023923A1 (de) * 1999-06-10 2000-12-14 Aventis Behring Gmbh Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen
US7153679B2 (en) * 2000-07-26 2006-12-26 Aventis Behring Gmbh Marburg I mutant of factor VII activating protease (FSAP) as risk factor for arterial thrombosis
EP1650305B1 (de) * 2000-07-26 2009-08-12 CSL Behring GmbH Mutanten der den Faktor VII aktivierenden Protease und Nachweisverfahren mit spezifischen Antikörpern
DE502006005169D1 (de) * 2005-12-22 2009-12-03 Siemens Healthcare Diagnostics Diagnostisches Verfahren zur Erkennung von Trägern der Marburg l-Variante der Faktor VII-aktivierenden Protease (FSAP) anhand differenzieller Modulation der FSAP-Aktivität
EP2395354A1 (de) 2010-06-10 2011-12-14 Siemens Healthcare Diagnostics Products GmbH Homogener Aktivitätstest zur Bestimmung von enzymatischen Reaktionen
CN108409863B (zh) * 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US124622A (en) * 1872-03-12 Improvement in canal-boats
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
GB9200417D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
DE19538716A1 (de) * 1995-10-18 1997-04-24 Behringwerke Ag Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa)
DE19903693A1 (de) * 1998-04-24 1999-10-28 Centeon Pharma Gmbh Protease zur Aktivierung des Gerinnungsfaktors VII
DE19937219A1 (de) 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie
DE10023923A1 (de) * 1999-06-10 2000-12-14 Aventis Behring Gmbh Verfahren zur Bestimmung der Aktivität der Faktor VII-aktivierenden Protease aus Proteinlösungen
DE19937218A1 (de) 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie
CA2405550A1 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
EP1650305B1 (de) * 2000-07-26 2009-08-12 CSL Behring GmbH Mutanten der den Faktor VII aktivierenden Protease und Nachweisverfahren mit spezifischen Antikörpern
DE10052319A1 (de) 2000-10-10 2002-04-11 Aventis Behring Gmbh Mutante der den Faktor VII aktivierenden Protease
DE10036641A1 (de) 2000-07-26 2002-02-14 Aventis Behring Gmbh Monoklonale Antikörper für die den Blutgerinnungsfaktor VII aktivierende Protease (FSAP)und ihre Verwendung
DE50114021D1 (de) * 2001-01-08 2008-07-24 Csl Behring Gmbh Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms
DE10148037A1 (de) * 2001-09-28 2003-04-17 Aventis Behring Gmbh Verwendung der den Blutgerinnungsfaktor VII aktivierenden Protease zur Prophylaxe und Therapie von vaso-proliferativen Erkrankungen
US7454400B2 (en) 2002-10-24 2008-11-18 Xerox Corporation System for negotiation with mirroring

Also Published As

Publication number Publication date
AU2003200420B2 (en) 2010-01-28
KR20030067588A (ko) 2003-08-14
US7829095B2 (en) 2010-11-09
AU2003200420A1 (en) 2003-08-28
DE50302926D1 (de) 2006-05-24
EP1334983A2 (de) 2003-08-13
EP1334983B1 (de) 2006-04-12
ATE323107T1 (de) 2006-04-15
DK1334983T3 (da) 2006-06-26
JP2003286300A (ja) 2003-10-10
US20030215447A1 (en) 2003-11-20
ES2259114T3 (es) 2006-09-16
CA2418411C (en) 2012-10-23
JP4398648B2 (ja) 2010-01-13
KR100972943B1 (ko) 2010-07-30
CA2418411A1 (en) 2003-08-08
EP1334983A3 (de) 2003-12-03

Similar Documents

Publication Publication Date Title
Highsmith et al. The inhibition of human plasmin by human antithrombin-heparin cofactor
DE19903693A1 (de) Protease zur Aktivierung des Gerinnungsfaktors VII
Kobayashi et al. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model
DE68922491T2 (de) Monoklonale antikörper gegen protein c.
EP0711838B2 (de) Verfahren zum spezifischen Nachweis eines aktivierten Gerinnungsfaktors V mit einer erhöhten Stabilität gegenüber aktiviertem Protein C
DE3607559A1 (de) Verfahren zur photometrischen bestimmung der protein c- und/oder protein s-aktivitaet
EP1334983B1 (de) Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII akitivierende Protease
Pixley et al. Effect of heparin on the activation of factor XII and the contact system in plasma
DE10309368A1 (de) Pharmazeutische Zubereitung mit RNA als Cofaktor der Hämostase
DE60003449T2 (de) Testverfahren
EP1650305B1 (de) Mutanten der den Faktor VII aktivierenden Protease und Nachweisverfahren mit spezifischen Antikörpern
EP0931793B1 (de) Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
Fukao et al. Tissue-type plasminogen activator, type 1 plasminogen activator inhibitor and their complex in plasma with disseminated intravascular coagulation
Weinberg et al. Biochemical properties of a bushmaster snake venom serine proteinase (LV-Ka), and its kinin releasing activity evaluated in rat mesenteric arterial rings
AT397391B (de) Verwendung von prothrombinfragmenten
DE69128557T2 (de) Verfahren zur Bestimmung eines Plasminogenaktivators und sein Inhibitor
Leung et al. Poly-D-lysine dependent inactivation of tissue plasminogen activator by a class PAI-2 inhibitor (minactivin)
DE3786098T2 (de) Bestimmungstest für der Thrombose verwandte Materialien.
AT404359B (de) Gereinigte multimerase
EP1664293A2 (de) Plasminogen-aktivatoren mit verringerter lysin-bindungskapazität
DE3782274T2 (de) Selektiver immunoassay fuer pro-urokinase und urokinase.
DE3804590A1 (de) Diagnostische sonden zum nachweis von elastase-modifiziertem antithrombin und verfahren zur behandlung
Thornton et al. Interaction of bovine factor IIa with an inhibitor from bovine plasma
JPH0377900A (ja) 血漿因子、その精製方法およびそれを有効成分として含有する血栓溶解剤

Legal Events

Date Code Title Description
8127 New person/name/address of the applicant

Owner name: ZLB BEHRING GMBH, 35041 MARBURG, DE

8130 Withdrawal